02:16 PM EST, 11/13/2025 (MT Newswires) -- IGC Pharma ( IGC ) said Thursday the US Patent and Trademark Office has granted the company a patent titled "Methods and Composition for Treating CNS Disorders."

The patent covers the formulation used in IGC-AD1, its lead drug candidate being evaluated in the phase 2 trial for agitation in Alzheimer's disease, the clinical-stage biotechnology firm said.

Price: 0.36, Change: -0.01, Percent Change: -1.64